An Oncologist's Approach to Therapy for Cutaneous T-Cell Lymphoma
Identifieur interne : 001B41 ( Main/Exploration ); précédent : 001B40; suivant : 001B42An Oncologist's Approach to Therapy for Cutaneous T-Cell Lymphoma
Auteurs : Francine M. Foss [États-Unis]Source :
- Clinical Lymphoma [ 1526-9655 ] ; 2000.
Abstract
Cutaneous T-cell lymphoma (CTCL) includes a heterogeneous group of diseases manifested in many cases by a prolonged clinical course. Even patients with advanced clinical disease, including erythroderma, adenopathy, and cutaneous tumors, can respond to a number of conservative therapeutic modalities, including radiation, cutaneous and extracorporeal phototherapy, and interferon. More aggressive systemic therapies are generally reserved for patients with visceral involvement or effaced (LN4) lymph node disease or patients refractory to multiple conservative approaches. Since no survival benefit has been demonstrated for multiagent cytotoxic chemotherapy regimens, this therapy is generally reserved for patients whose disease demonstrates an aggressive clinical course requiring immediate palliation. Durable responses (5 years) have been reported with purine analogues; however, prolonged immunosuppression and increased frequency of opportunistic infections have been demonstrated. Novel therapeutic agents, including interleukin-2, interleukin-12, the phosphorylase inhibitor peldesine (BCX-34), and bexarotene, have demonstrated activity. The interleukin-2 diphtheria toxin fusion protein, DAB389IL-2, has demonstrated a 30 response rate in advanced and refractory CTCL patients. The optimal role of targeted biological therapies in advanced patients will likely be in the minimal disease setting following either chemotherapy or radiation.
Url:
DOI: 10.3816/CLM.2000.s.002
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>An Oncologist's Approach to Therapy for Cutaneous T-Cell Lymphoma</title><author><name sortKey="Foss, Francine M" sort="Foss, Francine M" uniqKey="Foss F" first="Francine M." last="Foss">Francine M. Foss</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C93FD29A098B8C87F1415D844EAC3436D6ECCDF1</idno><date when="2000" year="2000">2000</date><idno type="doi">10.3816/CLM.2000.s.002</idno><idno type="url">https://api.istex.fr/document/C93FD29A098B8C87F1415D844EAC3436D6ECCDF1/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003162</idno><idno type="wicri:Area/Main/Curation">002D63</idno><idno type="wicri:Area/Main/Exploration">001B41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">An Oncologist's Approach to Therapy for Cutaneous T-Cell Lymphoma</title><author><name sortKey="Foss, Francine M" sort="Foss, Francine M" uniqKey="Foss F" first="Francine M." last="Foss">Francine M. Foss</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Tufts New England Medical Center, Boston</wicri:cityArea></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: francine.foss@es.nemc.org</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Lymphoma</title><title level="j" type="abbrev">CLOLD</title><idno type="ISSN">1526-9655</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">1</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="S9">S9</biblScope><biblScope unit="page" to="S14">S14</biblScope></imprint><idno type="ISSN">1526-9655</idno></series><idno type="istex">C93FD29A098B8C87F1415D844EAC3436D6ECCDF1</idno><idno type="DOI">10.3816/CLM.2000.s.002</idno><idno type="PII">S1526-9655(11)70278-0</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1526-9655</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cutaneous T-cell lymphoma (CTCL) includes a heterogeneous group of diseases manifested in many cases by a prolonged clinical course. Even patients with advanced clinical disease, including erythroderma, adenopathy, and cutaneous tumors, can respond to a number of conservative therapeutic modalities, including radiation, cutaneous and extracorporeal phototherapy, and interferon. More aggressive systemic therapies are generally reserved for patients with visceral involvement or effaced (LN4) lymph node disease or patients refractory to multiple conservative approaches. Since no survival benefit has been demonstrated for multiagent cytotoxic chemotherapy regimens, this therapy is generally reserved for patients whose disease demonstrates an aggressive clinical course requiring immediate palliation. Durable responses (5 years) have been reported with purine analogues; however, prolonged immunosuppression and increased frequency of opportunistic infections have been demonstrated. Novel therapeutic agents, including interleukin-2, interleukin-12, the phosphorylase inhibitor peldesine (BCX-34), and bexarotene, have demonstrated activity. The interleukin-2 diphtheria toxin fusion protein, DAB389IL-2, has demonstrated a 30 response rate in advanced and refractory CTCL patients. The optimal role of targeted biological therapies in advanced patients will likely be in the minimal disease setting following either chemotherapy or radiation.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Foss, Francine M" sort="Foss, Francine M" uniqKey="Foss F" first="Francine M." last="Foss">Francine M. Foss</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C93FD29A098B8C87F1415D844EAC3436D6ECCDF1
|texte= An Oncologist's Approach to Therapy for Cutaneous T-Cell Lymphoma
}}
| This area was generated with Dilib version V0.6.23. |  |